183 filings
Page 2 of 10
8-K
85mv0x gi
12 Dec 12
Unigene’s Phase 2 Study of Oral PTH for the Treatment of Osteoporosis in Postmenopausal Women Featured in Bone
12:00am
8-K
71giht5u7wn
11 Dec 12
Unigene Engages Financial Advisor to Explore Strategic Options and Advance Corporate Objectives
12:00am
8-K
63iv3
10 Dec 12
Departure of Directors or Certain Officers
12:00am
8-K
ulle68a
27 Nov 12
Unigene and Tarix Pharmaceuticals Enter Definitive Licencing Agreement for “Peptelligence-engineered” TXA127
12:00am
8-K
1rv3qa
27 Nov 12
Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
12:00am
8-K
7ee06hlray
21 Nov 12
Unigene Announces Third Quarter 2012 Corporate Update
12:00am
8-K
qs62srcv 53f
9 Nov 12
Other Events
12:00am
8-K
gf700odw
16 Oct 12
Results Presented at ASBMR 2012 Show Oral Calcitonin Improves Bone Mineral Density at Lumbar Spine
12:00am
8-K
t8l o2jfjqjn
3 Oct 12
Departure of Directors or Certain Officers
12:00am
8-K
0x2zxy c4
26 Sep 12
Unigene to Target Partnering and Therapeutic Development Opportunities Following Victory Park Capital Debt Financing and Forbearance
12:00am
8-K
uirogsiuw8f0 tgfb4j
19 Sep 12
Unigene and Tarix Pharmaceuticals Report Highly Increased Oral
12:00am
8-K
pq1w20x
7 Sep 12
Departure of Directors or Certain Officers
12:00am
8-K
gxpba2e x3
16 Aug 12
Departure of Directors or Certain Officers
12:00am
8-K
l1d5c hl2lsg84
15 Aug 12
Unigene and Nordic Bioscience Announce Preliminary Selection of Lead Compound for Treating Type 2 Diabetes
12:00am
8-K
fwvhna p8u
9 Aug 12
Unigene Announces Second Quarter 2012 Financial Results
12:00am
8-K
ldi3piq ftqlxi11emnd
26 Jul 12
Other Events
12:00am
8-K
7xiz7
23 Jul 12
Regulation FD Disclosure
12:00am
8-K
o9gw96uq
12 Jun 12
Departure of Directors or Certain Officers
12:00am
8-K
nex19g
8 Jun 12
Regulation FD Disclosure
12:00am
8-K
4u46g
6 Jun 12
Departure of Directors or Certain Officers
12:00am